BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) had its price objective lowered by Barclays from $12.00 to $10.00 in a research note released on Friday, The Fly reports.
A number of other analysts have also commented on the stock. Evercore ISI raised shares of BioCryst Pharmaceuticals from an in-line rating to an outperform rating and lifted their target price for the stock from $14.00 to $16.00 in a report on Wednesday, November 2nd. Royal Bank of Canada decreased their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set a sector perform rating for the company in a research note on Wednesday, November 2nd. Finally, StockNews.com began coverage on BioCryst Pharmaceuticals in a research note on Wednesday, October 12th. They issued a hold rating on the stock. Six investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Hold and a consensus price target of $16.43.
Get BioCryst Pharmaceuticals alerts:BioCryst Pharmaceuticals Stock Down 2.8 %
BioCryst Pharmaceuticals stock opened at $10.63 on Friday. The business's 50-day simple moving average is $12.54 and its 200 day simple moving average is $12.39. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -10.12 and a beta of 1.96. BioCryst Pharmaceuticals has a 12-month low of $7.61 and a 12-month high of $19.99.
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) last issued its earnings results on Tuesday, November 1st. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.09. The business had revenue of $75.83 million during the quarter, compared to the consensus estimate of $73.45 million. As a group, sell-side analysts expect that BioCryst Pharmaceuticals will post -1.15 EPS for the current year.Insider Buying and Selling at BioCryst Pharmaceuticals
In related news, insider Yarlagadda S. Babu sold 31,515 shares of the business's stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $13.88, for a total value of $437,428.20. Following the completion of the transaction, the insider now directly owns 298,541 shares in the company, valued at approximately $4,143,749.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other BioCryst Pharmaceuticals news, CEO Jon P. Stonehouse sold 14,100 shares of the stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $10.90, for a total transaction of $153,690.00. Following the completion of the transaction, the chief executive officer now owns 887,730 shares in the company, valued at approximately $9,676,257. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Yarlagadda S. Babu sold 31,515 shares of the business's stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $13.88, for a total value of $437,428.20. Following the completion of the sale, the insider now owns 298,541 shares in the company, valued at $4,143,749.08. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 146,141 shares of company stock valued at $1,862,013. Company insiders own 5.00% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the company. Semmax Financial Advisors Inc. boosted its position in BioCryst Pharmaceuticals by 389.6% during the 1st quarter. Semmax Financial Advisors Inc. now owns 1,699 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 1,352 shares during the last quarter. Fairfield Bush & CO. bought a new stake in shares of BioCryst Pharmaceuticals in the first quarter worth $34,000. Lazard Asset Management LLC acquired a new position in BioCryst Pharmaceuticals during the first quarter worth $57,000. Huntington National Bank grew its position in BioCryst Pharmaceuticals by 24.0% in the third quarter. Huntington National Bank now owns 5,582 shares of the biotechnology company's stock valued at $70,000 after purchasing an additional 1,081 shares in the last quarter. Finally, Amundi bought a new position in BioCryst Pharmaceuticals in the second quarter valued at $86,000. 80.68% of the stock is currently owned by institutional investors.
About BioCryst Pharmaceuticals
(Get Rating)
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
See Also
- Get a free copy of the StockNews.com research report on BioCryst Pharmaceuticals (BCRX)
- Can Chewy Fetch Double Digit Gains in 2023?
- 5 Down But Not Out Stocks To Watch For 2023
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
- Four Profitable RV Stocks To Ride Out Recession
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.